Dendritic cells from patients with chronic myeloid leukemia: Functional and phenotypic features

被引：11
作者：
Eisendle, K
Wolf, D
Gastl, G
Kircher-Eibl, B
机构：
[1] Innsbruck Med Univ, Dept Dermatol, A-6020 Innsbruck, Austria
[2] Innsbruck Med Univ, Lab Tumor & Immunobiol, Div Hematol & Oncol, Innsbruck, Austria
来源：
LEUKEMIA & LYMPHOMA | 2005年 / 46卷 / 05期
关键词：
CML; dendritic cell; immunotherapy; imatinib mesylate; T cell; tumor necrosis factor-alpha; vaccination;
D O I：
10.1080/10428190400029825
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Dendritic cells (DCs) are professional antigen-presenting cells playing a pivotal role in the induction of humoral and cellular immune responses, and chronic myeloid leukemia-derived DCs (CML-DCs) are possible candidates for inducing anti-leukemic immunity. This review describes phenotypic and functional features of DCs derived from CML patients as compared with DCs from healthy volunteers. In short, distinct deficiencies have been reported for CML-DCs, such as reduced migration, endocytosis, phagocytosis, antigen processing, DC maturation and cytokine production. DC abnormalities of CML patients can be abrogated by proper in vitro stimulation of leukemic DCs. This underscores the importance of proper generation and maturation of CML-DCs when considering clinical vaccination protocols.
引用
收藏
页码：663 / 670
页数：8
相关论文
共 68 条
[1]   Cutting edge: Dendritic cell actin cytoskeletal polarization during immunological synapse formation is highly antigen-dependent [J].
Al-Alwan, MM ;
Liwski, RS ;
Haeryfar, SMM ;
Baldridge, WH ;
Hoskin, DW ;
Rowden, G ;
West, KA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (09) :4479-4483
[2]   Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells [J].
Appel, S ;
Boehmler, AM ;
Grünebach, F ;
Müller, MR ;
Rupf, A ;
Weck, MM ;
Hartmann, U ;
Reichardt, VL ;
Kanz, L ;
Brümmendorf, TH ;
Brossart, P .
BLOOD, 2004, 103 (02) :538-544
[3]  
Bertazzoli C, 2000, CLIN CANCER RES, V6, P1931
[4]   Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate [J].
Boissel, N ;
Rousselot, P ;
Raffoux, E ;
Cayuela, JM ;
Maarek, O ;
Charron, D ;
Degos, L ;
Dombret, H ;
Toubert, A ;
Rea, D .
LEUKEMIA, 2004, 18 (10) :1656-1661
[5]  
Buchdunger E, 1996, CANCER RES, V56, P100
[6]   EXPRESSION OF RELB IS REQUIRED FOR THE DEVELOPMENT OF THYMIC MEDULLA AND DENDRITIC CELLS [J].
BURKLY, L ;
HESSION, C ;
OGATA, L ;
REILLY, C ;
MARCONI, LA ;
OLSON, D ;
TIZARD, R ;
CATE, R ;
LO, D .
NATURE, 1995, 373 (6514) :531-536
[7]   Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502
[8]   A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia [J].
Cathcart, K ;
Pinilla-Ibarz, J ;
Korontsvit, T ;
Schwartz, J ;
Zakhaleva, V ;
Papadopoulos, EB ;
Scheinberg, DA .
BLOOD, 2004, 103 (03) :1037-1042
[9]   Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia [J].
Choudhury, A ;
Gajewski, JL ;
Liang, JC ;
Popat, U ;
Claxton, DF ;
Kliche, KO ;
Andreeff, M ;
Champlin, RE .
BLOOD, 1997, 89 (04) :1133-1142
[10]   Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [J].
Clark, RE ;
Dodi, IA ;
Hill, SC ;
Lill, JR ;
Aubert, G ;
Macintyre, AR ;
Rojas, J ;
Bourdon, A ;
Bonner, PLR ;
Wang, LH ;
Christmas, SE ;
Travers, PJ ;
Creaser, CS ;
Rees, RC ;
Madrigal, JA .
BLOOD, 2001, 98 (10) :2887-2893
1234567